Advanced Therapies Enable Long-Term Survival in Multiple Myeloma Patients Through Second Stem Cell Transplants
Key Insights
Hospitals report significant success in treating multiple myeloma (search) with advanced therapies, including second autologous stem cell transplants showing improved long-term survival rates.
A 77-year-old woman successfully underwent a second autologous stem cell transplant after relapsing seven years post-initial diagnosis, achieving complete remission despite her advanced age.
Treatment evolution includes replacement of conventional chemotherapy with targeted therapies, central role of daratumumab in induction regimens, and proven safety of second transplants when performed after three-year intervals.
Hospitals are reporting significant success in treating multiple myeloma (search), with patients undergoing advanced therapies, including second autologous stem cell transplants, exhibiting improved long-term survival rates. These developments represent a major advancement in managing this complex blood cancer, particularly for elderly patients who previously had limited treatment options.
Breakthrough Cases Demonstrate Treatment Success
Dr. Shyam Aggarwal, Chairperson of Medical Oncology at Sir Ganga Ram Hospital, reported the case of a 77-year-old woman who successfully underwent a second autologous stem cell transplant after relapsing seven years following her initial diagnosis. Despite her advanced age, the disease was successfully managed due to advanced treatment protocols.
"She was first diagnosed at the age of 70 and received induction therapy with the VRD regimen (bortezomib, lenalidomide, and dexamethasone), followed by an autologous stem cell transplant. She remained on maintenance therapy with lenalidomide and zoledronic acid for five years," said Dr. Aggarwal.
At relapse, the patient was treated with a daratumumab-based four-drug induction regimen for eight weeks, followed by high-dose chemotherapy and a second stem cell transplant. Despite her advanced age, she tolerated the treatment well, was hospitalized for 17 days, and received supportive care including blood and platelet transfusions, antibiotics, and antifungal medications. She is now in complete remission and continues maintenance therapy with lenalidomide and denosumab, a bone-strengthening agent.
Long-Term Survival Outcomes
In another significant case, a 70-year-old man first presented in 1999 with severe back pain. MRI of the spine revealed multiple lytic lesions and destruction of the L1-L2 vertebrae. He underwent surgical removal of soft tissue and spinal fixation, and a biopsy confirmed the presence of abnormal plasma cells, establishing the diagnosis of IgG Kappa multiple myeloma (search).
Initially, he received the VAD chemotherapy protocol (vincristine, adriamycin, and dexamethasone), which was the standard of care at the time. After four cycles, he achieved remission and underwent autologous peripheral blood stem cell transplantation. He tolerated high-dose melphalan chemotherapy well and was discharged within three weeks, then placed on maintenance therapy with thalidomide and zoledronic acid for five years.
He remained stable until 2015, when he developed back pain again and was diagnosed with a relapse. This time, he was treated with a targeted three-drug regimen of bortezomib, lenalidomide, and dexamethasone. After responding well, he underwent a second autologous stem cell transplant, as the interval since his first transplant exceeded three years. His follow-up tests, including serum electrophoresis, immunofixation, and free light chain assays, remain normal, and he continues to lead an active life free of active disease.
Evolution of Treatment Approaches
Dr. Aggarwal highlighted four major changes in myeloma management over the years. Conventional chemotherapy has largely been replaced by targeted therapies in initial treatment. Daratumumab, a CD38 (search) monoclonal antibody, now plays a central role in induction regimens. Maintenance therapy with agents such as zoledronic acid or denosumab has helped prevent skeletal complications. Importantly, second autologous stem cell transplants have proven to be safe and effective when performed after a gap of more than three years.
Future Treatment Landscape
"Very few patients in earlier years underwent two stem cell transplants and survived long-term. Today, with newer drugs such as daratumumab, carfilzomib, and bispecific antibodies like teclistamab, we are achieving prolonged disease control," said Dr. Aggarwal.
He added that emerging treatments such as CAR-T cell therapy are expected to further improve outcomes in relapsed and refractory myeloma. These cases underscore the remarkable advances in multiple myeloma (search) care and offer renewed hope to patients battling this complex blood cancer.